Composition for skin improvement comprising lactic acid bacteria-derived pdrn

Abstract

The present disclosure relates to a composition for improving skin comprising PDRN derived from lactic acid bacteria. Specifically, the present disclosure relates to a PDRN composition derived from lactic acid bacteria comprising a PDRN extract derived from lactic acid bacteria and a dead cell of said lactic acid bacteria, and a composition for improving skin comprising the same.

Description

Technology Field

[0001] The present disclosure relates to a skin improvement composition comprising PDRN derived from lactic acid bacteria. Background Technology

[0002] With the recent increase in various cosmetic procedures and growing interest, there is also a growing number of cases where functional materials used in these procedures are being developed and commercialized for use in cosmetics or food products.

[0003] PDRN (Polydeoxyribonucleotide) is a tissue regeneration active substance that promotes the self-regeneration of damaged cells and tissues, and is a DNA polymer with a molecular weight of approximately 50 to 1,500 kDa. Unlike ordinary DNA, PDRN does not transmit genetic information but exhibits pharmacological activity. By stimulating A2 receptors, which are skin regeneration signaling pathways, it promotes the secretion of various growth factors, facilitates the formation of capillaries via Vascular Endothelial Growth Factor (VEGF), improves blood circulation, provides anti-inflammatory effects, and prevents capillary leakage.

[0004] In addition, PDRN is always present in human cells and acts to help maintain optimal condition by physiologically stimulating the regeneration and metabolic activity of fibroblasts. PDRN is receiving much attention due to research results showing that it is effective in treating wounds caused by burns and other injuries by promoting skin regeneration without specific side effects. It is known to shorten wound healing time and activate cell regeneration through rapid tissue regeneration, simultaneously promote the production of collagen and noncollagen proteins, and possess anti-inflammatory effects by promoting the differentiation of various cells (stem cells, fibroblasts, osteoblasts, chondrocytes, etc.).

[0005] Since PDRN is a DNA polymer and a biological component, it has the advantage of not causing allergic reactions or in vivo rejection reactions that occur with synthetic materials. Most PDRN raw materials are derived from fish; DNA is extracted from the sperm and testes of fish such as salmon, and PDRN is then purified in large quantities for use. Although the efficacy of this animal-derived PDRN extracted from salmon germ cells is well known, it has disadvantages: it is a very expensive raw material because it can only be extracted from germ cells, which are a very small part of the salmon; it also poses the risk of mass mortality and infection of fish; and it is unsuitable for the recently preferred 'vegan' or 'cruelty-free' products. Against this backdrop, prior art regarding PDRN derived from seaweed or plant cells rather than fish germ cells has recently been reported; however, due to the difficulties and complexity of mass production, there are limitations in terms of purity and price competitiveness that prevent widespread commercialization. Prior art literature

[0006] Korean Registered Patent Publication No. 10-2453167 The problem to be solved

[0007] The present disclosure aims to provide a composition with excellent skin improvement effects, such as wound healing, skin regeneration, wrinkle improvement, pore tightening, elasticity enhancement, and moisturization, by mixing non-animal, safe, high-yield, high-purity PDRN derived from lactic acid bacteria with dead lactic acid bacteria cells. means of solving the problem

[0008] To achieve the above objective, one embodiment of the present invention provides a lactic acid bacteria-derived PDRN composition comprising a lactic acid bacteria-derived PDRN extract and a dead cell of said lactic acid bacteria.

[0009] In addition, one embodiment of the present invention provides a skin improvement composition comprising a lactic acid bacteria-derived PDRN composition. Effects of the invention

[0010] The lactic acid bacteria-derived PDRN composition according to the present disclosure can have excellent skin improvement effects, such as wound healing, skin regeneration, wrinkle improvement, pore tightening, elasticity enhancement, and moisturization, by using a mixture of non-animal, safe, high-yield, high-purity PDRN derived from lactic acid bacteria and dead lactic acid bacteria cells. Brief explanation of the drawing

[0011] Figures 1a and 1b show the results of cell experiments on wound healing and skin regeneration efficacy according to Test Example 1. Figures 2a and 2b show the experimental results confirming the synergistic effect on wound healing and skin regeneration efficacy of the lactic acid bacteria-derived PDRN composition and collagen peptide according to Test Example 2. Figure 3 shows the positive improvement rate by strength of skin improvement efficacy according to Test Example 3. Specific details for implementing the invention

[0012] The present invention will be described in detail below.

[0013] In one aspect, the present invention may relate to a lactic acid bacteria-derived PDRN composition comprising a lactic acid bacteria-derived PDRN extract and a dead cell of said lactic acid bacteria.

[0014] In one embodiment, the PDRN extract may have a DNA content of 10% by weight or more relative to the total dry weight of the extract.

[0015] Specifically, the PDRN extract may have a DNA content of 10% by weight or more, 11% by weight or more, 12% by weight or more, or 13% by weight or more relative to the total dry weight of the extract.

[0016] As such, the lactic acid bacteria-derived PDRN extract according to one embodiment of the present invention is a high-purity PDRN extract containing 10% by weight or more of DNA by culturing lactic acid bacteria, separating and purifying PDRN within nucleic acid, and then removing unnecessary culture products such as lactic acid and dead cells, etc., and the lactic acid bacteria-derived PDRN composition can be obtained by separately mixing dead cells of lactic acid bacteria, which are inactivated cells that have undergone a heat treatment process after culturing lactic acid bacteria and contain both the metabolic products of the culture and the cells, with the above.

[0017] That is, the lactic acid bacteria-derived PDRN composition according to one embodiment of the present invention comprises a high-purity PDRN extract derived from lactic acid bacteria and dead lactic acid bacteria, and does not include excipients such as dextrin and culture products such as lactic acid.

[0018] In one embodiment, at least 90% of the DNA in the PDRN extract may have a molecular weight of 25 kDa or less.

[0019] Specifically, at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the DNA in the PDRN extract may have a molecular weight of 25 kDa or less, 23 kDa or less, 20 kDa or less, 19 kDa or less, 18 kDa or less, 17 kDa or less, 16 kDa or less, 15 kDa or less, 14 kDa or less, 13 kDa or less, or 12 kDa or less, and additionally, at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the DNA in the PDRN extract may have a molecular weight of 10 kDa or more, 11 It may be kDa or more, 12 kDa or more, 13 kDa or more, 14 kDa or more, 15 kDa or more, 16 kDa or more, 17 kDa or more, 18 kDa or more, or 19 kDa or more.

[0020] In one embodiment, the dead cells of the lactic acid bacteria are 1 x 10 10 Up to 1 X 10 14 It may be included in the above lactic acid bacteria-derived PDRN composition at a concentration of cells / g.

[0021] Specifically, the dead cells of the above lactic acid bacteria are 1 x 10 10 cells / g or more, 1 X 10 11 cells / g or more, 1 X 10 12 cells / g or more, 5 X 10 12 cells / g or more or 1 X 10 13 It may be included in the above lactic acid bacteria-derived PDRN composition at a concentration of cells / g or higher, and also 1 X 10 14 cells / g or less, 1 X 10 13 cells / g or less, 1 X 10 12 cells / g or less or 1 x 10⁶ 11 It may be included in the above lactic acid bacteria-derived PDRN composition at a concentration of cells / g or less.

[0022] In one embodiment, the lactic acid bacteria is Lactibacillus plantarum ( Lactiplantibacillus plantarum )(Previous name: Lactobacillus plantarum, Lactobacillus plantarum ) may be. More specifically, the above lactic acid bacterium is Lactibactibacillus plantarum APsulloc 331261( Lactiplantibacillus plantarum APsulloc 331261)(Previous name: Lactobacillus plantarum APsulloc 331261, Lactobacillus plantarum It may be APsulloc 331261) (Korean Culture Center of Microorganisms, accession number KCCM11179P, date of accession 20110328).

[0023] In one embodiment, the dead cells of the lactic acid bacteria and the lactic acid bacteria-derived PDRN extract may be included in a weight ratio of 1 to 20:1 (dead cells of lactic acid bacteria: lactic acid bacteria-derived PDRN extract).

[0024] Specifically, the weight ratio of the dead cells of the lactic acid bacteria to the PDRN extract derived from the lactic acid bacteria may be 1:1 or more, 2:1 or more, 3:1 or more, 4:1 or more, 5:1 or more, 6:1 or more, 7:1 or more, 8:1 or more, 9:1 or more, 10:1 or more, 11:1 or more, 12:1 or more, 13:1 or more, 14:1 or more, 15:1 or more, 16:1 or more, 17:1 or more, 18:1 or more, or 19:1 or more, and additionally, 20:1 or less, 19:1 or less, 18:1 or less, 17:1 or less, 16:1 or less, 15:1 or less, 14:1 or less, 13:1 or less, 12:1 or less, 11:1 It may be less than or equal to 10:1, less than or equal to 9:1, less than or equal to 8:1, less than or equal to 7:1, less than or equal to 6:1, less than or equal to 5:1, less than or equal to 4:1, less than or equal to 3:1, or less than or equal to 2:1.

[0026] In another aspect, the present invention may relate to a skin-improving composition comprising the above-mentioned lactic acid bacteria-derived PDRN composition.

[0027] In one embodiment, the lactic acid bacteria-derived PDRN composition may be treated to skin cells at a concentration of 0.1 to 10 ppm (w / v).

[0028] Specifically, the above lactic acid bacteria-derived PDRN composition is 0.1 ppm (w / v) or more, 0.2 ppm (w / v) or more, 0.3 ppm (w / v) or more, 0.4 ppm (w / v) or more, 0.5 ppm (w / v) or more, 0.6 ppm (w / v) or more, 0.7 ppm (w / v) or more, 0.8 ppm (w / v) or more, 0.9 ppm (w / v) or more, 1 ppm (w / v) or more, 1.5 ppm (w / v) or more, 2 ppm (w / v) or more, 2.5 ppm (w / v) or more, 3 ppm (w / v) or more, 3.5 ppm (w / v) or more, 4 ppm (w / v) or more, 4.5 ppm (w / v) or more, 5 ppm (w / v) or more, 5.5 ppm (w / v) Skin cells may be treated at a concentration of 6 ppm (w / v) or more, 6.5 ppm (w / v) or more, 7 ppm (w / v) or more, 7.5 ppm (w / v) or more, 8 ppm (w / v) or more, 8.5 ppm (w / v) or more, 9 ppm (w / v) or more, or 9.5 ppm (w / v) or more, and additionally, the above lactic acid bacteria-derived PDRN composition may be treated at a concentration of 10 ppm (w / v) or less, 9.5 ppm (w / v) or less, 9 ppm (w / v) or less, 8.5 ppm (w / v) or less, 8 ppm (w / v) or less, 7.5 ppm (w / v) or less, 7 ppm (w / v) or less, 6.5 ppm (w / v) or less, 6 ppm (w / v) or less, 5.5 ppm (w / v) or less, 5 Skin cells can be treated at concentrations of ppm(w / v) or less, 4.5 ppm(w / v) or less, 4 ppm(w / v) or less, 3.5 ppm(w / v) or less, 3 ppm(w / v) or less, 2.5 ppm(w / v) or less, 2 ppm(w / v) or less, 1.5 ppm(w / v) or less, 1 ppm(w / v) or less, 0.9 ppm(w / v) or less, 0.8 ppm(w / v) or less, 0.7 ppm(w / v) or less, 0.6 ppm(w / v) or less, 0.5 ppm(w / v) or less, 0.4 ppm(w / v) or less, 0.3 ppm(w / v) or less, or 0.2 ppm(w / v) or less.

[0029] In one embodiment, the lactic acid bacteria-derived PDRN composition may be included in an amount of 0.001 to 10 weight percent relative to the total weight of the skin improvement composition.

[0030] Specifically, the above-mentioned lactic acid bacteria-derived PDRN composition is present in an amount of 0.001 wt% or more, 0.005 wt% or more, 0.01 wt% or more, 0.05 wt% or more, 0.1 wt% or more, 0.2 wt% or more, 0.3 wt% or more, 0.4 wt% or more, 0.5 wt% or more, 0.6 wt% or more, 0.7 wt% or more, 0.8 wt% or more, 0.9 wt% or more, 1 wt% or more, 1.5 wt% or more, 2 wt% or more, 2.5 wt% or more, 3 wt% or more, 3.5 wt% or more, 4 wt% or more, 4.5 wt% or more, 5 wt% or more, 5.5 wt% or more, 6 wt% or more, 6.5 wt% or more, 7 wt% or more, 7.5 wt% or more, 8 wt% or more, 8.5 wt% or more, 9 wt% or more, based on the total weight of the composition for skin improvement. It may be included in an amount of 9.5 wt% or more, and furthermore, the lactic acid bacteria-derived PDRN composition may be included in an amount of 10 wt% or less, 9.5 wt% or less, 9 wt% or less, 8.5 wt% or less, 8 wt% or less, 7.5 wt% or less, 7 wt% or less, 6.5 wt% or less, 6 wt% or less, 5.5 wt% or less, 5 wt% or less, 4.5 wt% or less, 4 wt% or less, 3.5 wt% or less, 3 wt% or less, 2.5 wt% or less, 2 wt% or less, 1.5 wt% or less, 1 wt% or less, 0.9 wt% or less, 0.8 wt% or less, 0.7 wt% or less, 0.6 wt% or less, 0.5 wt% or less, 0.4 wt% or less, 0.3 wt% or less, 0.2 wt% or less, 0.1 wt% or less, 0.05 wt% or less, based on the total weight of the composition for skin improvement. It may be included in an amount of 0.01 weight% or less or 0.005 weight% or less.

[0031] In one embodiment, the skin improvement composition may further include collagen peptides.

[0032] In one embodiment, the collagen peptide comprises a Gly-Xaa-Yaa tripeptide of at least 15% by weight relative to the total weight of the collagen peptide, wherein Xaa and Yaa may each be independently selected from proline (Pro), hydroxyproline (Hyp), and alanine (Ala).

[0033] In one embodiment, the Gly-Xaa-Yaa tripeptide may comprise at least 3% by weight of Gly-Pro-Hyp (GPH) peptide relative to the total weight of the tripeptide.

[0034] In one embodiment, the skin improvement may be one or more selected from the group consisting of wound healing, promotion of skin regeneration, improvement of skin wrinkles, enhancement of skin elasticity, reduction of pores, skin moisturization, skin soothing, and skin whitening.

[0035] In one embodiment, the skin-improving composition may be a food composition, a health functional food composition, or a non-therapeutic oral composition.

[0036] In one embodiment, the daily intake of the lactic acid bacteria-derived PDRN composition may be 0.01 to 20 mg / kg.

[0037] Specifically, the daily intake of the above lactic acid bacteria-derived PDRN composition is 0.01 mg / kg or more, 0.02 mg / kg or more, 0.03 mg / kg or more, 0.04 mg / kg or more, 0.05 mg / kg or more, 0.06 mg / kg or more, 0.07 mg / kg or more, 0.08 mg / kg or more, 0.09 mg / kg or more, 0.1 mg / kg or more, 0.2 mg / kg or more, 0.3 mg / kg or more, 0.4 mg / kg or more, 0.5 mg / kg or more, 0.6 mg / kg or more, 0.7 mg / kg or more, 0.8 mg / kg or more, 0.9 mg / kg or more, 1 mg / kg or more, 2 mg / kg or more, 3 mg / kg or more, 4 mg / kg or more, 5 mg / kg or more, 6 mg / kg or more, 7 mg / kg or more, 8 mg / kg or more, 9 The daily intake of the above lactic acid bacteria-derived PDRN composition may be 20 mg / kg or less, 19 mg / kg or less, 18 mg / kg or less, 14 mg / kg or more, 15 mg / kg or more, 16 mg / kg or more, 17 mg / kg or more, 18 mg / kg or more, or 19 mg / kg or more, and additionally, the daily intake of the above lactic acid bacteria-derived PDRN composition may be 20 mg / kg or less, 19 mg / kg or less, 18 mg / kg or less, 17 mg / kg or less, 16 mg / kg or less, 15 mg / kg or less, 14 mg / kg or less, 13 mg / kg or less, 2 mg / kg or less, 11 mg / kg or less, 10 mg / kg or less, 9 mg / kg or less, 8 mg / kg or less, 7 mg / kg or less, 6 mg / kg or less, 5 mg / kg or less, 4 mg / kg or less, 3 mg / kg or less, 2 mg / kg or less, 1 mg / kg or less, 0.9 mg / kg or less, 0.8 mg / kg or less, 0.7 mg / kg or less, 0.6 mg / kg or less, 0.5 mg / kg or less, 0.4 mg / kg or less, 0.3 mg / kg or less, 0.2 mg / kg or less, 0.1 mg / kg or less, 0.09 mg / kg or less, 0.08 mg / kg or less, 0.07 mg / kg or less, 0.It may be 0.6 mg / kg or less, 0.05 mg / kg or less, 0.04 mg / kg or less, 0.03 mg / kg or less, or 0.02 mg / kg or less.

[0039] In one embodiment, the formulation of the food composition or non-therapeutic oral composition is not particularly limited, but may be formulated, for example, into tablets, granules, pills, powders, liquids such as drinks, caramels, gels, bars, tea bags, etc. In addition to the active ingredient, the composition of each formulation may be formulated by a person skilled in the art without difficulty by appropriately selecting and combining ingredients commonly used in the field according to the formulation or purpose of use, and a synergistic effect may occur when applied simultaneously with other raw materials.

[0040] In one embodiment, the food composition or non-therapeutic oral composition may be administered by various methods, such as simple ingestion, drinking, injection, spray, or squeeze administration.

[0041] In one embodiment, the food composition or non-therapeutic oral composition may be, for example, various food products such as chewing gum, chocolate, caramel products, candies, frozen desserts, confectionery, etc., beverage products such as soft drinks, mineral water, alcoholic beverages, etc., or health functional foods containing vitamins or minerals.

[0042] In one embodiment, the food composition or non-therapeutic oral composition may be consumed as is or used together with other foods or food ingredients and may be appropriately used according to conventional methods. The food composition or non-therapeutic oral composition may include a food-gradely acceptable food additive in addition to the peptide or its salt, and the amount of the active ingredient may be appropriately determined according to the purpose of use.

[0043] In this specification, the term "food auxiliary additive" refers to a component that can be added to food as an auxiliary component, and is added to the manufacture of health functional foods of each formulation, and can be appropriately selected and used by a person skilled in the art. Examples of food auxiliary additives include various nutritional supplements, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, coloring agents and fillers, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc., but the types of food auxiliary additives of the present invention are not limited by the above examples.

[0044] In this specification, the term "health functional food" refers to a food manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, etc., using raw materials or ingredients having functional properties useful to the human body. Here, "functional properties" means obtaining effects useful for health purposes, such as regulating nutrients or physiological actions regarding the structure and function of the human body. The health functional food of the present invention may be manufactured by methods commonly used in the ordinary technical field, and may be manufactured by adding raw materials and ingredients commonly added in the ordinary technical field during such manufacturing. Furthermore, the formulation of the health functional food may also be manufactured without limitation as long as it is a formulation recognized as a health functional food. The food composition may be manufactured in various forms of formulations.

[0046] In one embodiment, the skin improvement composition may be a pharmaceutical composition. Specifically, the skin improvement composition may be a pharmaceutical composition for wound healing and promoting skin regeneration.

[0047] In one embodiment, the daily dosage of the lactic acid bacteria-derived PDRN composition may be 0.01 to 10 mg / kg.

[0048] Specifically, the daily dosage of the above lactic acid bacteria-derived PDRN composition is 0.01 mg / kg or more, 0.02 mg / kg or more, 0.03 mg / kg or more, 0.04 mg / kg or more, 0.05 mg / kg or more, 0.06 mg / kg or more, 0.07 mg / kg or more, 0.08 mg / kg or more, 0.09 mg / kg or more, 0.1 mg / kg or more, 0.2 mg / kg or more, 0.3 mg / kg or more, 0.4 mg / kg or more, 0.5 mg / kg or more, 0.6 mg / kg or more, 0.7 mg / kg or more, 0.8 mg / kg or more, 0.9 mg / kg or more, 1 mg / kg or more, 2 mg / kg or more, 3 mg / kg or more, 4 mg / kg or more, 5 mg / kg or more, 6 mg / kg or more, 7 mg / kg or more, 8 mg / kg or more, or 9 It may be mg / kg or more, and additionally, the daily dosage of the above lactic acid bacteria-derived PDRN composition is 10 mg / kg or less, 9 mg / kg or less, 8 mg / kg or less, 7 mg / kg or less, 6 mg / kg or less, 5 mg / kg or less, 4 mg / kg or less, 3 mg / kg or less, 2 mg / kg or less, 1 mg / kg or less, 0.9 mg / kg or less, 0.8 mg / kg or less, 0.7 mg / kg or less, 0.6 mg / kg or less, 0.5 mg / kg or less, 0.4 mg / kg or less, 0.3 mg / kg or less, 0.2 mg / kg or less, 0.1 mg / kg or less, 0.09 mg / kg or less, 0.08 mg / kg or less, 0.07 mg / kg or less, 0.06 mg / kg or less, 0.05 mg / kg or less, 0.04 mg / kg or less, 0.03 mg / kg or less, or It may be 0.02 mg / kg or less.

[0049] In one embodiment, the pharmaceutical composition may be prepared in a unit volume form or contained in a multi-volume container by formulation using a pharmaceutically acceptable carrier and / or excipient according to a method that can be easily carried out by a person skilled in the art to which the present invention belongs. In this case, the formulation may be in the form of a solution, suspension, or emulsion in an oil or aqueous medium, or in the form of an extract, powder, granule, tablet, capsule, or gel (e.g., hydrogel), and may additionally include a dispersant or a stabilizer.

[0050] In one embodiment, the lactic acid bacteria-derived PDRN composition comprising the pharmaceutical composition may be carried on a pharmaceutically acceptable carrier such as a colloidal suspension, powder, saline solution, lipid, liposome, microsphere, or nano-spherical particle. These may form a complex with or be associated with a transport means and may be delivered in vivo using a transport system known in the art such as lipid, liposome, microparticle, gold, nanoparticle, polymer, condensation agent, polysaccharide, polyamino acid, dendrimer, saponin, adsorption enhancing substance, or fatty acid.

[0051] In addition, the above pharmaceutically acceptable carrier may include, but is not limited to, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia, rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methylcellulose, methylhydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil, which are commonly used in formulations. Furthermore, in addition to the above components, it may additionally include lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives, etc.

[0052] In one embodiment, the pharmaceutical composition may be administered orally or parenterally and may be used in the form of a general pharmaceutical formulation. That is, the pharmaceutical composition of the present invention may be administered in various oral and parenteral dosage forms; when formulated, it is prepared using diluents or excipients such as commonly used fillers, volume expanders, binders, wetting agents, disintegrants, and surfactants. Solid dosage forms for oral administration include tablets, pills, powders, granules, and capsules, and these solid dosage forms are prepared by mixing at least one excipient, for example, starch, calcium carbonate, sucrose or lactose, gelatin, etc., with a herbal extract or fermented herbal product. In addition, lubricants such as magnesium stirate and talc are also used in addition to simple excipients. Liquid formulations for oral administration include suspensions, oral liquids, emulsions, and syrups; in addition to commonly used simple diluents such as water and liquid paraffin, they may contain various excipients, such as humectants, sweeteners, flavorings, and preservatives. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspension solvents. Witepsol, Macrogol, Tween 61, cacao oil, laurin oil, glycerol, and gelatin may be used as bases for suppositories.

[0053] In one embodiment, the pharmaceutical composition may be a topical skin preparation. The topical skin preparation is a formulation in a form that can be applied to the outside of the skin. When the pharmaceutical composition of the present invention is used as a topical skin preparation, it may be applied to skin that has been wounded or to skin whose cell tissue has been damaged by physical stimulation. The topical skin preparation may be a cream, gel, ointment, skin emulsifier, skin suspension, transdermal patch, drug-containing bandage, lotion, or a combination thereof. The topical skin preparation may be appropriately formulated as needed with ingredients commonly used in topical skin preparations such as cosmetics or pharmaceuticals, for example, aqueous ingredients, oily ingredients, powder ingredients, alcohols, moisturizers, thickeners, UV absorbers, whitening agents, preservatives, antioxidants, surfactants, fragrances, colorants, various skin nutrients, or combinations thereof. The above topical preparation may also appropriately incorporate metal chelating agents such as disodium edetate, trisodium edetate, sodium citrate, sodium polyphosphate, sodium metaphosphate, and gluconic acid; caffeine, tannin, bellapamil, licorice extract, glablidin, hot water extract of the fruit of Carinus, various herbal medicines, preparations such as tocopherol acetate, glycyrrhizic acid, tranexamic acid and its derivatives or salts thereof, vitamin C, magnesium ascorbate phosphate, ascorbic acid glucoside, arbutin, kojic acid, glucose, fructose, trehalose, etc.

[0054] In one embodiment, the skin-improving composition may be a cosmetic composition.

[0055] In one embodiment, the daily application amount of the lactic acid bacteria-derived PDRN composition may be 0.01 to 10 mg / kg.

[0056] Specifically, the daily application amount of the above-mentioned lactic acid bacteria-derived PDRN composition is 0.01 mg / kg or more, 0.02 mg / kg or more, 0.03 mg / kg or more, 0.04 mg / kg or more, 0.05 mg / kg or more, 0.06 mg / kg or more, 0.07 mg / kg or more, 0.08 mg / kg or more, 0.09 mg / kg or more, 0.1 mg / kg or more, 0.2 mg / kg or more, 0.3 mg / kg or more, 0.4 mg / kg or more, 0.5 mg / kg or more, 0.6 mg / kg or more, 0.7 mg / kg or more, 0.8 mg / kg or more, 0.9 mg / kg or more, 1 mg / kg or more, 2 mg / kg or more, 3 mg / kg or more, 4 mg / kg or more, 5 mg / kg or more, 6 mg / kg or more, 7 mg / kg or more, 8 mg / kg or more, or 9 It may be mg / kg or more, and additionally, the daily application amount of the above lactic acid bacteria-derived PDRN composition is 10 mg / kg or less, 9 mg / kg or less, 8 mg / kg or less, 7 mg / kg or less, 6 mg / kg or less, 5 mg / kg or less, 4 mg / kg or less, 3 mg / kg or less, 2 mg / kg or less, 1 mg / kg or less, 0.9 mg / kg or less, 0.8 mg / kg or less, 0.7 mg / kg or less, 0.6 mg / kg or less, 0.5 mg / kg or less, 0.4 mg / kg or less, 0.3 mg / kg or less, 0.2 mg / kg or less, 0.1 mg / kg or less, 0.09 mg / kg or less, 0.08 mg / kg or less, 0.07 mg / kg or less, 0.06 mg / kg or less, 0.05 mg / kg or less, 0.04 mg / kg or less, 0.03 mg / kg or less, or It may be 0.02 mg / kg or less.

[0057] In one embodiment, the cosmetic composition may include a cosmetically effective amount of the lactic acid bacteria-derived PDRN composition and a cosmetically acceptable carrier, wherein the cosmetically effective amount means an amount sufficient to achieve the aforementioned skin improvement efficacy.

[0058] In one embodiment, the cosmetic composition may additionally contain other ingredients that have the characteristic of providing a synergistic effect on the activity of the lactic acid bacteria-derived PDRN composition, for example, within a range that does not affect the skin improvement activity of the lactic acid bacteria-derived PDRN composition. For example, it may contain auxiliary ingredients commonly used in the field of cosmetics or dermatology, such as fatty substances, organic solvents, solvents, thickeners and gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or non-ionic emulsifiers, fillers, metal ion chelating agents and chelating agents, preservatives, vitamins, blockers, humectants, essential oils, dyes, pigments, fragrances, hydrophilic or lipophilic active agents, lipid vesicles, or any other ingredients commonly used in cosmetics, and said ingredients may be contained in amounts commonly used in the field of cosmetics or dermatology.

[0059] In one embodiment, the cosmetic composition is not particularly limited in its formulation and can be appropriately selected according to the purpose. For example, it may be prepared in one or more formulations selected from the group consisting of skin lotion, skin softener, skin toner, astringent, serum, lotion, milk lotion, moisture lotion, nourishing lotion, massage cream, nourishing cream, moisture cream, hand cream, foundation, essence, nourishing essence, pack, soap, cleansing foam, cleansing lotion, cleansing cream, cleansing oil, body lotion, body cleanser, body cream, and body oil, but is not limited thereto.

[0060] In one embodiment, the cosmetic composition may be prepared in any formulation commonly manufactured in the art, for example, a solution, suspension, emulsion, paste, powder, gel, cream, lotion, soap, oil, and spray, but is not limited thereto.

[0061] In the case where the formulation of the above cosmetic composition is a paste, cream, or gel, animal oil, vegetable oil, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, or zinc oxide may be used as a carrier component.

[0062] In the case where the formulation of the above cosmetic composition is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder may be used as a carrier component, and in particular, in the case of a spray, it may additionally include a propellant such as chlorofluorohydrocarbon, propane / butane, or dimethyl ether.

[0063] When the formulation of the above cosmetic composition is a solution or an emulsion, a solvent, a solubilizing agent, or an emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol, or fatty acid ester of sorbitan.

[0064] In the case where the formulation of the above cosmetic composition is a suspension, liquid diluents such as water, ethanol, or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, or tracanth may be used as carrier components.

[0065] In addition to the active ingredient and carrier ingredient, the ingredients included in the above cosmetic composition include ingredients commonly used in topical skin compositions, and may include, for example, conventional auxiliary agents such as antioxidants, stabilizers, solubilizers, vitamins, pigments, and fragrances.

[0067] As one embodiment, the present invention may provide the following embodiments.

[0068] A first embodiment may provide a lactic acid bacteria-derived PDRN composition comprising a lactic acid bacteria-derived PDRN extract and a dead cell of the lactic acid bacteria.

[0069] The second embodiment can provide a lactic acid bacteria-derived PDRN composition, wherein, in the first embodiment, the PDRN extract has a DNA content of 10% by weight or more relative to the total dry weight of the extract.

[0070] In the third embodiment, in one or more of the first and second embodiments, the dead cells of the lactic acid bacteria are 1 x 10 10 Up to 1 X 10 14 A composition of lactic acid bacteria-derived PDRN containing cells / g concentration can be provided.

[0071] The fourth embodiment is, in one or more of the first to third embodiments, the lactic acid bacteria is Lactibactibacillus plantarum ( Lactiplantibacillus plantarum A PDRN composition derived from lactic acid bacteria can be provided.

[0072] The fifth embodiment may provide a skin-improving composition comprising a lactic acid bacteria-derived PDRN composition according to one or more of the first to fourth embodiments.

[0073] The sixth embodiment may provide a lactic acid bacteria-derived PDRN composition in which, in one or more of the first to fifth embodiments, the dead cells of the lactic acid bacteria and the lactic acid bacteria-derived PDRN extract are included in a weight ratio of 1 to 20:1.

[0074] The seventh embodiment can provide a skin-improving composition in which, in the sixth embodiment, the lactic acid bacteria-derived PDRN composition is treated to skin cells at a concentration of 0.1 to 10 ppm (w / v).

[0075] The eighth embodiment may provide a skin-improving composition in which, in one or more of the sixth to seventh embodiments, the lactic acid bacteria-derived PDRN composition is included in an amount of 0.001 to 10 weight% relative to the total weight of the skin-improving composition.

[0076] The ninth embodiment may provide a skin-improving composition that further comprises a collagen peptide in one or more of the sixth to eighth embodiments.

[0077] The 10th embodiment may provide a skin-improving composition, wherein, in one or more of the 6th to 9th embodiments, the collagen peptide comprises a Gly-Xaa-Yaa tripeptide in an amount of 15% by weight or more relative to the total weight of the collagen peptide, wherein Xaa and Yaa are each independently selected from proline (Pro), hydroxyproline (Hyp), and alanine (Ala).

[0078] The 11th embodiment may provide a skin-improving composition in which, in one or more of the 6th to 10th embodiments, the Gly-Xaa-Yaa tripeptide comprises at least 3% by weight of Gly-Pro-Hyp (GPH) peptide relative to the total weight of the tripeptide.

[0079] The 12th embodiment may provide a skin improvement composition in which, in one or more of the 6th to 11th embodiments, the skin improvement is one or more selected from the group consisting of wound healing, promotion of skin regeneration, improvement of skin wrinkles, enhancement of skin elasticity, reduction of pores, skin moisturization, skin soothing, and skin whitening.

[0080] The 13th embodiment may provide a skin-improving composition in which, in one or more of the 6th to 12th embodiments, the skin-improving composition is a pharmaceutical, cosmetic, or health functional food composition.

[0082] The contents of the present invention will be explained in more detail below through examples and test examples. However, these examples and test examples are provided merely to help understand the contents of the present invention, and the scope of the present invention is not limited to these examples and test examples. Modifications, substitutions, and insertions commonly known in the art may be performed, and such are also included within the scope of the present invention.

[0084] Example 1. Preparation of a lactic acid bacteria-derived PDRN composition

[0085] 1-1. Preparation of a lactic acid bacteria-derived PDRN composition

[0086] Lactiplantibacillus plantarum APsulloc 331261 ( Lactiplantibacillus plantarum Lactic acid bacteria (APsulloc 331261) were inoculated and cultured at 37°C for more than 20 hours. Cells were separated by centrifugation at 6,000 rpm for 15 minutes, and unnecessary culture products such as lactic acid were removed. Subsequently, PDRN and dead cells contained within the cells were separated and recovered by hot-pressure crushing under conditions of 121°C, 15 psi, and 15-30 minutes. The recovered PDRN extract and dead cells were then mixed and dried to prepare a lactic acid bacteria-derived PDRN composition.

[0087] 1-2. Verification of the purity of lactic acid bacteria-derived PDRN extract

[0088] To confirm the purity of the lactic acid bacteria-derived PDRN extract obtained by excluding dead cells (precipitate) after dissolving the lactic acid bacteria-derived PDRN composition prepared in Example 1-1 in ultrapure water and centrifuging at 15,000 rpm for 15 minutes, the final concentration was analyzed by absorbance analysis under ds_DNA quantification conditions using a spectrophotometer (UV-Vis spectrophotometer, Agilent). Specifically, 0.5 g of the lactic acid bacteria-derived PDRN extract was dissolved in 19.5 mL of ultrapure water, centrifuged, and then analyzed five times on a sample diluted 4,000 times, and the results are shown in Table 1 below.

[0089] Number of repetitions Final DNA concentration (concentration x 4,000) μg / mL DNA concentration Ratio μg / mL 260 / 280 260 / 230 PDRN-1 139,760 34.94 1.93 1.82 PDRN-2 137,560 34.39 1.97 1.89 PDRN-3 140,680 35.17 1.94 1.87 PDRN-4 140,760 35.19 2.06 1.81 PDRN-5 139,960 34.99 1.97 1.82

[0090] From the results of Table 1 above, it was confirmed that the PDRN extract derived from lactic acid bacteria according to one embodiment of the present invention has a final DNA concentration of an average of 139,744 μg / mL, which is at least 100,000 μg / mL, i.e., 10% (w / v) or higher, and the 260 / 280 ratio value and the 260 / 230 ratio value were measured to be 1.9 or higher and 1.8 or higher, respectively, confirming that it is a high-purity PDRN extract in which proteins and polysaccharides, etc., have been well removed.

[0091] 1-3. Confirmation of Molecular Weight of Lactic Acid Bacteria-Derived PDRN Extract

[0092] To confirm the molecular weight of the lactic acid bacteria-derived PDRN extract obtained in Examples 1-2 above, the molecular weight was analyzed using size exclusion chromatography. The test system used for the analysis is as follows:

[0093] - HPLC: LC-20AR; SHIMADZU

[0094] - Column: GFC-P3000; Phenomenex

[0095] - Mobile phase: 2x PBS

[0096] Specifically, the molecular weight of the lactic acid bacteria-derived PDRN extract obtained in Examples 1-2 above was analyzed three times using the above test system, and the results are shown in Table 2 below.

[0097] Retention time (minutes) Molecular weight (Da) Size (bp) PDRN-1 95.732 22,914.43 33.74 PDRN-2 95.307 21,707.67 31.97 PDRN-3 95.478 22,184.71 32.67 average 95.51 22,268.94 32.80

[0098] From the results of Table 2 above, it was confirmed that the weight-average molecular weight of the lactic acid bacteria-derived PDRN extract according to one embodiment of the present invention is approximately 22 kDa, and when calculated in terms of base pair unit size (bp) reflecting the average molecular weight of nucleotides and double-stranded DNA, it has a size of approximately 32 bp. In addition, it was confirmed that the lactic acid bacteria-derived PDRN extract according to one embodiment of the present invention has a significantly smaller molecular weight compared to the molecular weight of existing salmon-derived PDRN, which is 50 kDa to 1,500 kDa.

[0099] Test Example 1. Cellular experiment on skin improvement efficacy (HaCaT scratch analysis)

[0100] 5 x 10 human skin keratinocyte cell line HaCaT (Korea Cell Line Bank) in a 6-well plate 5After dispensing at concentrations, the cells were cultured for 24 hours at 37°C, 5% CO2 conditions until cell confluency reached 80–90%. The next day, the cell culture medium was removed, and scratches were made on the surface of the HaCaT cells using a 200p tip. After washing once with PBS, the cells were cultured for 48 hours with salmon-derived PDRN extract (DNActive, NutriSceine USA) (0.1, 10 μg / ml), the lactic acid bacteria-derived PDRN extract obtained in Example 1-2 (0.1, 10 μg / ml), and the lactic acid bacteria-derived PDRN composition prepared in Example 1-1 (i.e., lactic acid bacteria-derived PDRN extract + dead cells) (0.1 μg / ml). The degree of wound healing over time was observed using a microscope, and the area of ​​the remaining scratches was measured to relatively compare the area of ​​cell migration with a control group that was not treated with the samples. The results are shown in Fig. 1a and Fig. 1b.

[0101] As shown in FIGS. 1a and 1b, when the lactic acid bacteria-derived PDRN composition according to the present invention was treated at 0.1 μg / ml (0.1 ppm), the area of ​​the remaining scratch was the smallest, confirming that the wound healing efficacy through cell migration was the best. On the other hand, in the case of salmon-derived PDRN extract, the wound healing efficacy was found to be significantly lower compared to the lactic acid bacteria-derived PDRN composition, and when the lactic acid bacteria-derived PDRN extract was treated alone at 10 μg / ml (10 ppm), it was found to be effective, but significantly lower than the effect when treated with the lactic acid bacteria-derived PDRN composition at 0.1 ppm. From this, it was confirmed that the lactic acid bacteria-derived PDRN composition according to the present invention has the best wound healing effect even with only the lowest concentration of 0.1 ppm.

[0103] Test Example 2. Confirmation of synergistic effect between lactic acid bacteria-derived PDRN composition and collagen peptide

[0104] Wound healing efficacy was confirmed using the same method as in Test Example 1, except that the lactic acid bacteria-derived PDRN composition prepared in Example 1-1 (i.e., lactic acid bacteria-derived PDRN extract + dead cells) (0.1 μg / ml), APCP (AP collagen peptide) (0.1 μg / ml), and the lactic acid bacteria-derived PDRN composition prepared in Example 1-1 (0.1 μg / ml) + APCP (0.1 μg / ml) were each treated and cultured for 24 hours. At this time, the AP collagen peptide is a collagen peptide containing 15.0% or more of the tripeptide Gly-Xaa-Yaa (where Xaa and Yaa are proline, hydroxyproline, or alanine, respectively) containing 3% Gly-Pro-Hyp (GPH). Nemipterus virgatus It was produced by enzymatic hydrolysis of skin-derived collagen and obtained from Aestura. The results are shown in Figures 2a and 2b.

[0105] As shown in FIGS. 2a and 2b, there was a significant wound healing effect when treated with the lactic acid bacteria-derived PDRN composition according to the present invention, but it was confirmed that the wound healing effect was significantly enhanced when treated together with collagen peptide.

[0107] Test Example 3. Confirmation of skin improvement effect following ingestion of lactic acid bacteria-derived PDRN composition

[0108] To confirm the skin improvement effect of consuming a lactic acid bacteria-derived PDRN composition, a human efficacy evaluation was conducted on 39 healthy adult women aged 25 to under 50. Specifically, the lactic acid bacteria-derived PDRN composition prepared in Example 1-1 above was consumed once a day for 4 weeks at a dose of 250 mg / day or 500 mg / day, and then instrumental measurements were performed to confirm whether there was a skin improvement effect.

[0109] After photographing the subject's face using the Mark-Vu facial skin analyzer (PSI PLUS), the skin improvement efficacy of the lactic acid bacteria-derived PDRN composition was evaluated by dividing it into a total of nine categories: pores, wrinkles, future wrinkles, epidermal pigmentation, melanin, redness, porphyrin, elasticity, and transepidermal water loss. For each category, changes in the skin were checked before intake and after 4 weeks of intake, and the positive improvement rate was expressed as [(after 4 weeks of intake - before intake) * 100], and the results are shown in Figure 3.

[0110] As shown in Fig. 3, when a lactic acid bacteria-derived PDRN composition according to one embodiment of the present invention was consumed for 4 weeks, skin elasticity improved in 49% of subjects, and positive improvement effects were observed in 38% of subjects regarding wrinkles and porphyrins in 31% of subjects. In addition, positive improvements were observed in transepidermal water loss, redness, epidermal pigmentation, melanin, and pores, indicating that various skin improvement effects can be expected when consuming a lactic acid bacteria-derived PDRN composition.

Claims

Claim 1 A lactic acid bacteria-derived PDRN composition comprising a lactic acid bacteria-derived PDRN extract and a dead cell of said lactic acid bacteria. Claim 2 In claim 1, the PDRN extract is a lactic acid bacteria-derived PDRN composition having a DNA content of 10% by weight or more relative to the total dry weight of the extract. Claim 3 In claim 1, the dead cells of the lactic acid bacteria are 1 x 10 10 Up to 1 X 10 14 A composition of lactic acid bacteria-derived PDRN containing cells / g concentration. Claim 4 In claim 1, the lactic acid bacteria is Lactibacillus plantarum ( Lactiplantibacillus plantarum )Lactic acid bacteria-derived PDRN composition. Claim 5 A lactic acid bacteria-derived PDRN composition according to claim 1, wherein the dead cells of the lactic acid bacteria and the lactic acid bacteria-derived PDRN extract are included in a weight ratio of 1 to 20:

1. Claim 6 A composition for improving skin comprising a lactic acid bacteria-derived PDRN composition according to any one of claims 1 to 5. Claim 7 In claim 6, the above lactic acid bacteria-derived PDRN composition is a skin improvement composition that is treated to skin cells at a concentration of 0.1 to 10 ppm (w / v). Claim 8 A skin-improving composition according to claim 6, wherein the lactic acid bacteria-derived PDRN composition is included in an amount of 0.001 to 10 weight% relative to the total weight of the skin-improving composition. Claim 9 A skin-improving composition according to claim 6, further comprising collagen peptides. Claim 10 A skin-improving composition according to claim 9, wherein the collagen peptide comprises a Gly-Xaa-Yaa tripeptide in an amount of at least 15% by weight relative to the total weight of the collagen peptide, wherein Xaa and Yaa are each independently selected from proline (Pro), hydroxyproline (Hyp), and alanine (Ala). Claim 11 A skin-improving composition according to claim 10, wherein the Gly-Xaa-Yaa tripeptide comprises at least 3% by weight of Gly-Pro-Hyp (GPH) peptide relative to the total weight of the tripeptide. Claim 12 A skin improvement composition according to claim 6, wherein the skin improvement is one or more selected from the group consisting of wound healing, promotion of skin regeneration, improvement of skin wrinkles, enhancement of skin elasticity, reduction of pores, skin moisturization, skin soothing, and skin whitening. Claim 13 In claim 6, the skin-improving composition is a pharmaceutical, cosmetic, or health functional food composition.

Images